All In Biotech

Investigational drug · Phase 3

R-DXd

Also called: DS 6000a, MK-5909, raludotatug deruxtecan

Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

10

10 still active

All registered trials

12

Any phase or sponsor naming "R-DXd"

First trial start

2021

Aug 19, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "R-DXd", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cancer
  • Small Cell Lung Carcinoma
  • Ovarian Neoplasms
  • Solid Cancer
  • Advanced Solid Tumor
  • Metastatic Solid Tumors
  • Ovarian Cancer Recurrent
  • Lung Neoplasm

Approved drugs for the same conditions: Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "R-DXd" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Fallopian Tube Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • UtidelonePhase 38 trials

    Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

  • ZN-c3azenosertibPhase 34 trials

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma

  • H1 receptor antagonistPhase 33 trials

    Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer

  • HS-20089Phase 33 trials

    Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer

  • IBI354Phase 33 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.